| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 21.05.
| Active Biotech, Ipsen reach €10m milestone in Phase III study of tasquinimod | | 3 | Pharma Bus Review |
| 21.05.
| Active Biotech: 600 Patients Recruited in Active Biotech's and Ipsen's tasquinimod Clinical Phase III Study | | 91 | Thomson Reuters ONE |
| Half of target patient population recruited, triggering a €10 million milestone payment Lund (Sweden) and Paris (France), May 21, 2012, Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext:...
Mehr lesen zu:
Active Biotech: 600 Patients Recruited in Active Biotech's and Ipsen's tasquinimod Clinical Phase III Study | |
| 21.05.
| 600 Patients Recruited in Active Biotech's and Ipsen's tasquinimod Clinical Phase III Study | | 60 | Business Wire |
| Half of target patient population recruited, triggering a €10
million milestone payment
Regulatory News:
...
Mehr lesen zu:
600 Patients Recruited in Active Biotech's and Ipsen's tasquinimod Clinical Phase III Study | |
| 18.05.
| Active Biotech: Active Biotech and Ipsen to present Tasquinimod Phase II Overall Survival data at the 2012 ASCO Annual Meeting | | 37 | Thomson Reuters ONE |
| Lund (Sweden) and Paris (France), May 18, 2012, Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) will present tasquinimod (TASQ), their prostate cancer drug candidate...
Mehr lesen zu:
Active Biotech: Active Biotech and Ipsen to present Tasquinimod Phase II Overall Survival data at the 2012 ASCO Annual Meeting | |
| 18.05.
| Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting | | 46 | Business Wire |
| Regulatory News:
Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Paris:IPN)
(Euronext: IPN; ADR: IPSEY)
will present tasquinimod (TASQ),
...
Mehr lesen zu:
Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting | |
| 11.05.
| The 10th Endocrine Regulation Prize of the Fondation Ipsen is awarded to Paolo Sassone-Corsi | | 30 | Business Wire |
| (University of California, Irvine, United States)
The international jury under the presidency of Professor Iain Robinson (National
Institute for Medical...
Mehr lesen zu:
The 10th Endocrine Regulation Prize of the Fondation Ipsen is awarded to Paolo Sassone-Corsi | |
| 09.05.
| Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company | | 38 | Business Wire |
| Regulatory News:
(Article 223-16 of the General Regulations of the Autorité des
Marchés Financiers)
Ipsen (Paris:IPN)Market : NYSE Euronext...
Mehr lesen zu:
Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company | |
| 04.05.
| Ipsen: Combined Shareholders' Meeting of June 1, 2012 | | 60 | Business Wire |
| Availability of preparatory documentation for the Shareholders'
Meeting
Regulatory News:
Ipsen SA (Paris:IPN):
...
Mehr lesen zu:
Ipsen: Combined Shareholders' Meeting of June 1, 2012 | |
| 03.05.
| Ipsen's First Quarter 2012 Sales | | 60 | Business Wire |
| Strong Growth of Specialty Care Sales, up 9.7%1
Somatuline® up 17.5%1
Dysport® up 13.8%1
Primary Care...
Mehr lesen zu:
Ipsen's First Quarter 2012 Sales | |
| 26.04.
| Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders' Meeting to be held on June 1, 2012 | | 51 | Business Wire |
| Regulatory News:
Ipsen (Paris:IPN):
In accordance with the provisions of Article 241-2 of the General
Regulations of the Autorité des Marchés...
Mehr lesen zu:
Ipsen : Description of the share repurchase program proposed by the Board of directors to the approval of the Combined Shareholders' Meeting to be held on June 1, 2012 | |
| 25.04.
| Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ) | | 48 | Business Wire |
| Ipsen, State and Foreign Dignitaries Celebrate New Pharma Jobs in
NJ at Ipsen US Headquarters Ribbon-Cutting
Ipsen US Commercial Operations...
Mehr lesen zu:
Ipsen Pursues Its Development in the United States with the Opening of Its New Commercial Headquarters in New Jersey (NJ) | |
| 17.04.
| Ipsen's Partner, Inspiration Biopharmaceuticals, Announces US Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for the Treatment of Hemophilia B | | 75 | Business Wire |
| Regulatory News:
Ipsen (Paris:IPN) (Euronext: IPN, ADR: IPSEY) today announced that its
partner, Inspiration Biopharmaceuticals, Inc. (Inspiration), has
...
Mehr lesen zu:
Ipsen's Partner, Inspiration Biopharmaceuticals, Announces US Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for the Treatment of Hemophilia B | |
| 06.04.
| IPSEN : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company | | 60 | Business Wire |
| Regulatory News:
(Article 223-16 of the General Regulations of the Autorité des
Marchés Financiers)
IPSEN (Paris:IPN)Market : NYSE Euronext...
Mehr lesen zu:
IPSEN : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company | |
| 04.04.
| New Leadership Team for Ipsen Operations in North America to Drive Growth in Neurology and Endocrinology | | 26 | Business Wire |
| Sean McKercher, President and General Manager, North America,
appoints eight seasoned senior managers to executive positions to
advance operations
...
Mehr lesen zu:
New Leadership Team for Ipsen Operations in North America to Drive Growth in Neurology and Endocrinology | |
| 03.04.
| The 20th Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences Series: "Programmed Cells: from Basic Neuroscience to Therapy" | | 43 | Business Wire |
| Embryonic stem cells have the potential to become any type of cells
found in the body, including various types of nerve cells, but they have
several drawbacks, both ethical...
Mehr lesen zu:
The 20th Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences Series: "Programmed Cells: from Basic Neuroscience to Therapy" | |
| 02.04.
| The Ipsen Group publishes its 2011 Registration document | | 40 | Business Wire |
| Regulatory News:
Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) announced today that its
2011 Registration Document has been filed with the French "Autorité...
Mehr lesen zu:
The Ipsen Group publishes its 2011 Registration document | |
| 05.03.
| Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company | | 43 | Business Wire |
| Regulatory News:
Ipsen (Paris:IPN):
(Article 223-16 of the General Regulations of the Autorité des
Marchés Financiers)
...
Mehr lesen zu:
Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company | |
| 29.02.
| Ipsen's 2011 Results and 2012 Objectives | | 65 | Business Wire |
| Solid Operating Performance with a Recurring Adjusted1
Operating Profit of €200.7 Million, up 9.6%
Reported Operating Profit of €75.8 Million...
Mehr lesen zu:
Ipsen's 2011 Results and 2012 Objectives | |
| 28.02.
| The 27th Colloque Médecine et Recherche of the Fondation Ipsen in the Alzheimer Disease series: "Proteopathic Seeds and Neurodegenerative Diseases" | | 60 | Business Wire |
| In the mid 1980s, Stanley Prusiner startled the scientific world by
claiming that transmissible neurodegenerative diseases such as
Creutzfeldt-Jakob in humans and Bovine...
Mehr lesen zu:
The 27th Colloque Médecine et Recherche of the Fondation Ipsen in the Alzheimer Disease series: "Proteopathic Seeds and Neurodegenerative Diseases" | |
| 24.02.
| Active Biotech: Active Biotech and Ipsen report for the first time Tasquinimod (TASQ) phase II long term safety data at the 27th European Association of Urology (EAU) Congress | | 60 | Thomson Reuters ONE |
| Lund (Sweden) and Paris (France), February 24, 2012 - Active Biotech's (NASDAQ OMX NORDIC: ACTI) and Ipsen's (Euronext: IPN; ADR: IPSEY) castrate resistant prostate cancer project, TASQ will be presented...
Mehr lesen zu:
Active Biotech: Active Biotech and Ipsen report for the first time Tasquinimod (TASQ) phase II long term safety data at the 27th European Association of Urology (EAU) Congress | |
